(Q37011976)

17 August 2017

1 reference

title

Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer (English)

1 reference

head and neck squamous cell carcinoma

17 August 2017

1 reference

1 reference

1 reference

2

Lesley J Scott

1 reference

17 August 2017

Stephanie K A Blick

1

1 reference

17 August 2017

publication date

1 January 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

67

1 reference

17 August 2017

issue

17

1 reference

17 August 2017

page(s)

2585-2607

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200767170-00008

17 August 2017

exact match

0 references

cites work

Cetuximab: in the treatment of metastatic colorectal cancer

1 reference

12 December 2020

The biology of epidermal growth factor receptor and its value as a prognostic/predictive factor

1 reference

12 December 2020

Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor

1 reference

12 December 2020

Cetuximab in the treatment of metastatic colorectal cancer

1 reference

12 December 2020

Targeting epidermal growth factor receptor in head and neck cancer

1 reference

12 December 2020

Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck.

1 reference

12 December 2020

Circulating VEGF predicts efficacy of cetuximab

1 reference

12 December 2020

Epidermal growth factor receptor biology (IMC-C225).

1 reference

12 December 2020

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

1 reference

12 December 2020

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

1 reference

12 December 2020

Cetuximab-induced acne

1 reference

12 December 2020

In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.

1 reference

12 December 2020

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of advanced colorectal cancer

1 reference

12 December 2020

Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds

1 reference

12 December 2020

Epidermal growth factor receptor targeting in cancer

1 reference

12 December 2020

Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience

1 reference

12 December 2020

Effect of Epidermal Growth Factor Receptor Inhibitor Class in the Treatment of Head and Neck Cancer with Concurrent Radiochemotherapy In vivo

1 reference

12 December 2020

Cetuximab and radiotherapy for head and neck cancer

1 reference

12 December 2020

Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors

1 reference

12 December 2020

Facial hypertrichosis induced by Cetuximab, an anti-EGFR monoclonal antibody

1 reference

12 December 2020

Cetuximab for the treatment of colorectal cancer.

1 reference

12 December 2020

Molecular determinants of cetuximab efficacy

1 reference

12 December 2020

Cetuximab therapy and symptomatic hypomagnesemia

1 reference

12 December 2020

A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing

1 reference

12 December 2020

Incidence and management of cutaneous toxicities associated with cetuximab

1 reference

12 December 2020

Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications.

1 reference

12 December 2020

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

12 December 2020

Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts

1 reference

12 December 2020

The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer.

1 reference

12 December 2020

Cetuximab in the treatment of head and neck cancer

1 reference

12 December 2020

State-of-the-art management of locally advanced head and neck cancer

1 reference

12 December 2020

Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer

1 reference

12 December 2020

Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.

1 reference

12 December 2020

A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.

1 reference

12 December 2020

A case report and discussion of cetuximab-induced folliculitis.

1 reference

12 December 2020

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

1 reference

12 December 2020

Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment

1 reference

12 December 2020

Cetuximab-induced hypomagnesemia in patients with colorectal cancer.

1 reference

12 December 2020

1 reference

12 December 2020

Current status of cetuximab for the treatment of patients with solid tumors.

1 reference

12 December 2020

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

1 reference

12 December 2020

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

1 reference

12 December 2020

Epidermal growth factor receptor--its expression and copy numbers of EGFR gene in patients with head and neck squamous cell carcinomas

1 reference

12 December 2020

Abnormal hair growth in a patient with head and neck cancer treated with the anti-epidermal growth factor receptor monoclonal antibody cetuximab

1 reference

12 December 2020

The EGFR as a target for anticancer therapy--focus on cetuximab

1 reference

12 December 2020

Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies.

1 reference

12 December 2020

Cost of cancer care: issues and implications

1 reference

12 December 2020

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

12 December 2020

Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma

1 reference

12 December 2020

10.2165/00003495-200767170-00008

Identifiers

DOI

1 reference

Dimensions Publication ID

17 August 2017

1034984109

0 references

1 reference